Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies

P. Correale, D. Cerretani, M. Clerici, S. Messinese, S. Marsili, R. Petrioli, F. Cetta, V. Savelli, A. Guarnieri, E. Pinto, G. Giorgi, G. Francini

Research output: Contribution to journalArticlepeer-review


This phase II clinical trial was performed in order to evaluate the pharmacokinetics, toxicity and anti-tumor activity of a novel combination of gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) designed on a specific translational basis. Every 4 weeks, 44 patients with various gastroenteric malignancies, 29 of whom had pancreas carcinoma, received a short intravenous (i.v.) infusion of FA (100 mg/m2) and 5-FU (400 mg/m 2) on days 1-5, and GEM 1000 mg/m2 on days 1, 8 and 16. Our results suggest that, although this treatment leads to hematological and gastroenteric toxicity, it is very active in patients with pancreatic carcinoma. We therefore believe that an improved version would merit further investigation in larger scale trials.

Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalJournal of Chemotherapy
Issue number2
Publication statusPublished - Apr 2004


  • 5-Fluorouracil
  • Gastroenteric malignancies
  • Gemcitabine
  • Pancreas carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)


Dive into the research topics of 'Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in patients with different gastroenteric malignancies'. Together they form a unique fingerprint.

Cite this